Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-25 Substudy A – Brexucabtagene Autoleucel in Relapsed/Refractory Waldenstrom Macroglobulinemia
2022-501259-10-00Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Feb 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in Waldenström macroglobulinemia (WM), sponsored by Kite Pharma. Primary endpoint: Combined CR and VGPR rate by central assessment (Substudy A primary endpoint). Started Feb 2023; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2022-501259-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501259-10-00.